1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Rani Shares Positive Oral Ustekinumab Data After Last Year’s Challenges

RT-111 Oral Ustekinumab Biosimilar Passes Phase I Trial After Company Prioritization

 
• By Adam Zamecnik

Rani Therapeutics announced positive topline results from a Phase I trial of its oral Stelara biosimilar, moving it further in a crowded market with fierce competition.

Woman Taking Pill With Glass Of Water
The Oral Ustekinumab Biosimilar Passed Its Phase I Study • Source: Shutterstock

Rani Therapeutics has shared positive topline data from a Phase I trial of its orally administered biosimilar to Johnson & Johnson’s (J&J’s) Stelara (ustekinumab) known as RT-111 after undertaking strategic measures at the tail end of last year.

According to the San Diego, California-headquartered company, the biosimilar was well-tolerated among subjects recruited in the study, with no reports of serious adverse events

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By Dave Wallace

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By Dean Rudge

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.